Qingbi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Qingbi Zhang has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Jun Bai
Environmental Health Effects and Risk Assessment Key Laboratory of Luzhou, School of Public Health, Southwest Medical University, Luzhou 646000, Sichuan, PR China
7 shared publicationsYan Cui
Environmental Health Effects and Risk Assessment Key Laboratory of Luzhou, School of Public Health, Southwest Medical University, Luzhou, China
7 shared publications- Faqin Dong
School of Environment and Resource, Southwest University of Science and Technology, Mianyang, China
4 shared publications Hailan Wang
The Key Laboratory of Modern Toxicology, Ministry of Education, School of Public Health, Suzhou Institute for Advanced Study of Public Health, Gusu School, Nanjing Medical University, Nanjing 211166, Jiangsu, PR China; Center for Global Health, China International Cooperation Center for Environment and Human Health, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu, PR China
4 shared publications- Jun Bai
Environmental Health Effects and Risk Assessment Key Laboratory of Luzhou School of Public Health Southwest Medical University Luzhou China
4 shared publications Renjiang He
Environmental Health Effects and Risk Assessment Key Laboratory of Luzhou, School of Public Health, Southwest Medical University, Luzhou, China
4 shared publications
Latest Publications
- 5 June 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (9) , 107875
Antifungal and immunomodulatory activities of dihydroartemisinin-loaded chitosan nanoparticles against fluconazole‑resistant Candida tropicalis
- 5 June 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (9) , 107875
Antifungal and immunomodulatory activities of dihydroartemisinin-loaded chitosan nanoparticles against fluconazole‑resistant Candida tropicalis
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41345
Exploring the potential mechanisms of anti-pulmonary fibrosis effects of Luo Han Guo via network pharmacology, molecular docking, and experimental validation
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung condition distinguished by a complex etiology, poor prognosis and exhibiting high mortality rates. While therapeutic drugs are currently available, they often come with notable side effects. Luo Han Guo (LHG), a medicinal plant, is known for its properties in moistening the lungs, relieving cough, calming asthma, and resolving phlegm; however, systematic research on its potential therapeutic mechanisms and active ingredients for IPF is lacking. This study utilized network pharmacology to predict the active ingredients, key targets, and potential mechanisms of LHG's anti-IPF effects, followed by molecular docking simulations of the active ingredients and their potential targets, which were subsequently validated through in vivo experiments. From 91 potential targets of LHG, four key targets were identified. Analysis of the compound-target network diagram suggested that kaempferol, 11-oxomogroside V, and Mogrol may be the principal active compounds of LHG for treating IPF. Additionally, KEGG pathway enrichment analysis indicated that LHG might mitigate IPF through the PI3K/AKT and SRC/STAT3 pathways. In conclusion, this study provides preliminary insights into the active constituents and possible molecular mechanisms of LHG in alleviating IPF, offering a novel perspective for investigating the pharmacological effects of LHG in IPF treatment.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41345
Open AccessExploring the potential mechanisms of anti-pulmonary fibrosis effects of Luo Han Guo via network pharmacology, molecular docking, and experimental validation
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung condition distinguished by a complex etiology, poor prognosis and exhibiting high mortality rates. While therapeutic drugs are currently available, they often come with notable side effects. Luo Han Guo (LHG), a medicinal plant, is known for its properties in moistening the lungs, relieving cough, calming asthma, and resolving phlegm; however, systematic research on its potential therapeutic mechanisms and active ingredients for IPF is lacking. This study utilized network pharmacology to predict the active ingredients, key targets, and potential mechanisms of LHG's anti-IPF effects, followed by molecular docking simulations of the active ingredients and their potential targets, which were subsequently validated through in vivo experiments. From 91 potential targets of LHG, four key targets were identified. Analysis of the compound-target network diagram suggested that kaempferol, 11-oxomogroside V, and Mogrol may be the principal active compounds of LHG for treating IPF. Additionally, KEGG pathway enrichment analysis indicated that LHG might mitigate IPF through the PI3K/AKT and SRC/STAT3 pathways. In conclusion, this study provides preliminary insights into the active constituents and possible molecular mechanisms of LHG in alleviating IPF, offering a novel perspective for investigating the pharmacological effects of LHG in IPF treatment.
- Top Cited Papers
- 21 January 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 488, 137310
H4K12 lactylation-regulated NLRP3 is involved in cigarette smoke-accelerated Alzheimer-like pathology through mTOR-regulated autophagy and activation of microglia
- 21 January 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 488, 137310
Top Cited PapersH4K12 lactylation-regulated NLRP3 is involved in cigarette smoke-accelerated Alzheimer-like pathology through mTOR-regulated autophagy and activation of microglia
- 11 September 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (12) , 4047-4058
Interleukin-9 promotes EMT-mediated PM2.5-induced pulmonary fibrosis by activating the STAT3 pathway
This study investigated the impact of PM2.5 on promoting EMT in PM2.5-induced pulmonary fibrosis (PF) development and explored molecular mechanisms of the IL-9/STAT3/Snail/TWIST1 signaling pathway in PF owing to PM2.5. Four groups of male SD rats were formed: control (0 mg/kg.bw), low (1 mg/kg.bw), medium (5 mg/kg.bw), and high-dose (25 mg/kg.bw) PM2.5 groups. Experimental rats were subjected to PM2.5 exposure via intratracheal instillation, given once weekly for 16 weeks. 24 h after the final exposure, blood, BALF, and lung tissues were collected. Pulmonary epithelial cells underwent cultivation and exposure to varying PM2.5 concentrations with/without inhibitors for 24 h, after which total protein was extracted for relevant protein assays. The findings demonstrated that PM2.5 damaged lung tissue to different degrees and led to PF in rats. Rats subjected to PM2.5 exposure exhibited elevated concentrations of IL-9 protein in both serum and BALF, and elevated levels of IL-9 and its receptor, IL-9R, in lung tissues, compared to control counterparts. Furthermore, PM2.5-exposed groups demonstrated significantly augmented protein levels of p-STAT3, Snail, TWIST1, Vimentin, COL-I, and α-SMA, while displaying notably diminished levels of E-Cadherin compared to control group. The same findings were observed in PM2.5-treated cells. In BEAS-2B cells co-treated with Stattic (STAT3 inhibitor) and PM2.5, the opposite results occurred. Similar results were obtained for cells co-treated with IL-9-neutralizing antibody and PM2.5. Our findings suggest PM2.5 mediates PF development by promoting IL-9 expression, leading to STAT3 phosphorylation and upregulation of Snail and TWIST1 expression, triggering EMT occurrence and progression in lung epithelial cells.
- 11 September 2024
- Published by Springer Nature in Archives of Toxicology
- Vol. 98 (12) , 4047-4058
Interleukin-9 promotes EMT-mediated PM2.5-induced pulmonary fibrosis by activating the STAT3 pathway
This study investigated the impact of PM2.5 on promoting EMT in PM2.5-induced pulmonary fibrosis (PF) development and explored molecular mechanisms of the IL-9/STAT3/Snail/TWIST1 signaling pathway in PF owing to PM2.5. Four groups of male SD rats were formed: control (0 mg/kg.bw), low (1 mg/kg.bw), medium (5 mg/kg.bw), and high-dose (25 mg/kg.bw) PM2.5 groups. Experimental rats were subjected to PM2.5 exposure via intratracheal instillation, given once weekly for 16 weeks. 24 h after the final exposure, blood, BALF, and lung tissues were collected. Pulmonary epithelial cells underwent cultivation and exposure to varying PM2.5 concentrations with/without inhibitors for 24 h, after which total protein was extracted for relevant protein assays. The findings demonstrated that PM2.5 damaged lung tissue to different degrees and led to PF in rats. Rats subjected to PM2.5 exposure exhibited elevated concentrations of IL-9 protein in both serum and BALF, and elevated levels of IL-9 and its receptor, IL-9R, in lung tissues, compared to control counterparts. Furthermore, PM2.5-exposed groups demonstrated significantly augmented protein levels of p-STAT3, Snail, TWIST1, Vimentin, COL-I, and α-SMA, while displaying notably diminished levels of E-Cadherin compared to control group. The same findings were observed in PM2.5-treated cells. In BEAS-2B cells co-treated with Stattic (STAT3 inhibitor) and PM2.5, the opposite results occurred. Similar results were obtained for cells co-treated with IL-9-neutralizing antibody and PM2.5. Our findings suggest PM2.5 mediates PF development by promoting IL-9 expression, leading to STAT3 phosphorylation and upregulation of Snail and TWIST1 expression, triggering EMT occurrence and progression in lung epithelial cells.
- 14 July 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 400, 111144
The mechanism of interaction between tri-para-cresyl phosphate and human serum protein: A multispectroscopic and in-silico study
- 14 July 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 400, 111144
The mechanism of interaction between tri-para-cresyl phosphate and human serum protein: A multispectroscopic and in-silico study
- 15 December 2023
- Published by Elsevier in Science of The Total Environment
- Vol. 917, 169306
A proteomic study on gastric impairment in rats caused by microcystin-LR
- 15 December 2023
- Published by Elsevier in Science of The Total Environment
- Vol. 917, 169306
A proteomic study on gastric impairment in rats caused by microcystin-LR
- 19 July 2023
- Published by Wiley in Environmental Toxicology
- Vol. 38 (11) , 2608-2620
A novel mitochondria‐targeting compound exerts therapeutic effects against melanoma by inducing mitochondria‐mediated apoptosis and autophagy in vitro and in vivo
Melanoma is the most invasive skin cancer, with a high mortality rate. However, existing therapeutic drugs have side effects, low reactivity, and lead to drug resistance. As the power source in cells, mitochondria play an important role in the survival of cancer cells and are an important target for tumor therapy. This study aimed to develop a new anti‐melanoma compound that targets mitochondria, evaluate its effect on the proliferation and metastasis of melanoma cells, and explore its mechanism of action. The novel mitochondria‐targeting compound, SCZ0148, was synthesized by modifying the structure of cyanine. Then, A375 and B16 cells were incubated with different concentrations of SCZ0148, and different doses of SCZ0148 were administered to A375 and B16 xenograft zebrafish. The results showed that SCZ0148 targeted mitochondria, had dose‐ and time‐dependent effects on the proliferation of melanoma cell lines, and had no obvious side effects on normal cells. In addition, SCZ0148 induced melanoma cell apoptosis through the reactive oxygen species‐mediated mitochondrial pathway of apoptosis and promoted autophagy. SCZ0148 significantly inhibited the migration of melanoma cells via a matrix metalloprotein 9‐mediated pathway. Similarly, SCZ0148 inhibited melanoma cell proliferation in a concentration‐dependent manner in vivo. In summary, SCZ0148 may be a novel anti‐melanoma compound that targets mitochondria.
- 19 July 2023
- Published by Wiley in Environmental Toxicology
- Vol. 38 (11) , 2608-2620
A novel mitochondria‐targeting compound exerts therapeutic effects against melanoma by inducing mitochondria‐mediated apoptosis and autophagy in vitro and in vivo
Melanoma is the most invasive skin cancer, with a high mortality rate. However, existing therapeutic drugs have side effects, low reactivity, and lead to drug resistance. As the power source in cells, mitochondria play an important role in the survival of cancer cells and are an important target for tumor therapy. This study aimed to develop a new anti‐melanoma compound that targets mitochondria, evaluate its effect on the proliferation and metastasis of melanoma cells, and explore its mechanism of action. The novel mitochondria‐targeting compound, SCZ0148, was synthesized by modifying the structure of cyanine. Then, A375 and B16 cells were incubated with different concentrations of SCZ0148, and different doses of SCZ0148 were administered to A375 and B16 xenograft zebrafish. The results showed that SCZ0148 targeted mitochondria, had dose‐ and time‐dependent effects on the proliferation of melanoma cell lines, and had no obvious side effects on normal cells. In addition, SCZ0148 induced melanoma cell apoptosis through the reactive oxygen species‐mediated mitochondrial pathway of apoptosis and promoted autophagy. SCZ0148 significantly inhibited the migration of melanoma cells via a matrix metalloprotein 9‐mediated pathway. Similarly, SCZ0148 inhibited melanoma cell proliferation in a concentration‐dependent manner in vivo. In summary, SCZ0148 may be a novel anti‐melanoma compound that targets mitochondria.
- Open Access
- 30 December 2021
- Published by Springer Nature in Research Square
A Novel Small-Molecule Inhibitor Displays Its Therapeutic Potency Through Mitochondria-Mediated Apoptosis And Autophagy In Melanoma
Melanoma is the most aggressive skin cancer with high mortality. It is vital to develop novel low toxicity drugs with anti-proliferation activity and metastasis suppressive activity in melanoma. Here, we reported a novel anti-tumor drug SCZ0148, and then investigated its inhibition effect on melanoma. The anticancer efficacy of SCZ0148 was confirmed by using cytotoxicity test, colony formation assay, wound-healing assay, cell apoptosis detection, mitochondrial potential assay, reactive oxygen species (ROS) production and western-blot analysis. The cytotoxicity test showed that SCZ0148 inhibited melanoma cell lines proliferation in a dose- and time-dependent manner without obvious toxicity and side effects on normal cells. The results of the colony formation assay were in agreement with the cytotoxicity test. In addition, SCZ0148 induced melanoma cell apoptosis and promoted cell destructive autophagy through the ROS-mediated mitochondrial apoptosis pathway. Notably, SCZ0148 significantly inhibited the migration of melanoma cells through the matrix metalloprotein 9 (MMP-9) mediated pathway. In conclusion, these findings suggest that SCZ0148 may be a potential therapeutic drug to inhibit the proliferation and metastasis of melanoma.
- 30 December 2021
- Published by Springer Nature in Research Square
Open AccessA Novel Small-Molecule Inhibitor Displays Its Therapeutic Potency Through Mitochondria-Mediated Apoptosis And Autophagy In Melanoma
Melanoma is the most aggressive skin cancer with high mortality. It is vital to develop novel low toxicity drugs with anti-proliferation activity and metastasis suppressive activity in melanoma. Here, we reported a novel anti-tumor drug SCZ0148, and then investigated its inhibition effect on melanoma. The anticancer efficacy of SCZ0148 was confirmed by using cytotoxicity test, colony formation assay, wound-healing assay, cell apoptosis detection, mitochondrial potential assay, reactive oxygen species (ROS) production and western-blot analysis. The cytotoxicity test showed that SCZ0148 inhibited melanoma cell lines proliferation in a dose- and time-dependent manner without obvious toxicity and side effects on normal cells. The results of the colony formation assay were in agreement with the cytotoxicity test. In addition, SCZ0148 induced melanoma cell apoptosis and promoted cell destructive autophagy through the ROS-mediated mitochondrial apoptosis pathway. Notably, SCZ0148 significantly inhibited the migration of melanoma cells through the matrix metalloprotein 9 (MMP-9) mediated pathway. In conclusion, these findings suggest that SCZ0148 may be a potential therapeutic drug to inhibit the proliferation and metastasis of melanoma.